Why the study?
Does fondaparinux improve efficacy and safety in patients with non-ST elevation acute coronary syndromes or ST elevation myocardial infarction?
Does fondaparinux improve efficacy and safety in patients with non-ST elevation acute coronary syndromes or ST elevation myocardial infarction?
This report reviews the OASIS 5 and 6 trials evaluating fondaparinux in over 32,000 patients with acute coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Offers synthesis of fondaparinux in >32k ACS patients; leaves open its role versus newer agents.
Karthikeyan et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: